

# CITATION REPORT

List of articles citing

**Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study**

**DOI: 10.1097/01.ju.0000162035.73977.1c**  
**Journal of Urology, 2005, 174, 196-200.**

**Source:** <https://exaly.com/paper-pdf/39497248/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
507	Urologic applications of botox. <b>2005</b> , 6, 419-23		9
506	Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. <b>2005</b> , 66, 865-70; discussion 870		74
505	Improving the global management of the neurogenic bladder patient: part II. Future treatment strategies. <b>2006</b> , 22, 851-60		6
504	The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics. <b>2006</b> , 7, 529-38		13
503	Improving the global management of the neurogenic bladder patient: part I. The complexity of patients. <b>2006</b> , 22, 359-65		9
502	Botulinum Toxin in the Treatment of Neurogenic Bladder in Adults and Children. <b>2006</b> , 5, 679-684		5
501	Managing Patients with Neurogenic Detrusor Overactivity: A Global Approach. <b>2006</b> , 5, 691-695		1
500	Understanding the Role of Botulinum Toxin A in the Treatment of the Overactive Bladder: More than Just Muscle Relaxation. <b>2006</b> , 5, 670-678		10
499	Efficacy of Botulinum Toxin A in the Treatment of Female Idiopathic Detrusor Overactivity Incontinence: Long-Term Results of a Prospective Nonrandomised Study. <b>2006</b> , 5, 685-690		1
498	Botulinum toxin: From life-threatening disease to novel medical therapy. <b>2006</b> ,		
497	The case for bladder botulinum toxin application. <b>2006</b> , 33, 503-10, ix		12
496	[Pittsburgh experience with botulinum toxin A injection]. <b>2006</b> , 30, 310-4		6
495	Botulinum Toxin Type A Is a Safe and Effective Treatment for Neurogenic Urinary Incontinence: Results of a Single Treatment, Randomized, Placebo Controlled 6-Month Study. <b>2006</b> , 2006, 266-267		
494	Botulinum toxin for the management of bladder dysfunction. <b>2006</b> , 66, 1301-18		35
493	Botulinum toxin: a potential alternative to current treatment of neurogenic and idiopathic urinary incontinence due to detrusor overactivity. <b>2006</b> , 95, 305-11		7
492	Botulinum toxin: clinical use. <b>2006</b> , 12, 331-55		86
491	Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?. <b>2006</b> , 68, 993-7; discussion 997-8		60

490	Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. <b>2006</b> , 68, 1193-7	79
489	The challenge of overactive bladder therapy: alternative to antimuscarinic agents. <b>2006</b> , 32, 620-30	14
488	Botulinum toxin and the overactive bladder. <b>2006</b> , 67, 460-464	
487	CME Self-Assessment Exam. <b>2006</b> , 85, 545	
486	Pharmacotherapy for neurogenic detrusor overactivity. <b>2006</b> , 85, 536-45	74
485	Botulinum toxin in urinary incontinence. <b>2006</b> , 16, 255-60	5
484	Bibliography. Current world literature. Female urology. <b>2006</b> , 16, 310-3	
483	Current awareness: Pharmacoepidemiology and drug safety. <b>2006</b> , 15, i-xii	
482	Techniques for the intradetrusor administration of botulinum toxin. <b>2006</b> , 97, 675-8	19
481	What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?. <b>2006</b> , 97, 1030-4	52
480	Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. <b>2006</b> , 98, 77-82	53
479	Neuromodulatory therapies in female pelvic medicine and reconstructive surgery: biological agents. <b>2006</b> , 98 Suppl 1, 50-60; discussion 61	9
478	The management of neurogenic bladder and quality of life in spinal cord injury. <b>2006</b> , 98, 739-45	87
477	Refractory neurogenic detrusor overactivity. <b>2006</b> , 60, 22-6	5
476	Treatment-resistant detrusor overactivity--underlying pharmacology and potential mechanisms. <b>2006</b> , 60, 8-16	28
475	Integrative control of the lower urinary tract: preclinical perspective. <b>2006</b> , 147 Suppl 2, S25-40	305
474	Cystoscopy for gynaecologists. <b>2006</b> , 8, 78-85	2
473	Botulinum toxin in multiple sclerosis. <b>2006</b> , 253 Suppl 1, I16-20	15

472	Management of the neurogenic bladder in the female patient. <b>2006</b> , 1, 65-70	1
471	Urologic applications of botox. <b>2006</b> , 1, 99-103	
470	Evaluation and management of refractory overactive bladder. <b>2006</b> , 7, 370-5	0
469	Management of the neurogenic bladder in the female patient. <b>2006</b> , 7, 423-8	2
468	Refractory overactive bladder in men: update on novel therapies. <b>2006</b> , 7, 456-61	6
467	Management of bladder, prostatic and pelvic floor disorders. <b>2006</b> , 9, 161-72	8
466	Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. <b>2006</b> , 49, 519-27	58
465	Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. <b>2006</b> , 49, 644-50	250
464	Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. <b>2006</b> , 49, 528-35	94
463	Histologic features in the urinary bladder wall affected from neurogenic overactivity--a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. <b>2006</b> , 50, 1058-64	123
462	Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. <b>2006</b> , 50, 684-709; discussion 709-10	71
461	Botulinum toxin and the overactive bladder. <b>2006</b> , 67, 460-4	0
460	Botulinum toxin and its orthopaedic applications. <b>2006</b> , 88, 981-7	25
459	Role of gap junctions in spontaneous activity of the rat bladder. <b>2007</b> , 293, F1018-25	112
458	Successful treatment with botulinum toxin A after failed augmentation ileocystoplasty. <b>2007</b> , 4, 280-4	12
457	Inkontinenz nach Schlaganfall - Fast jeder Zweite ist betroffen - Inaktivität und/oder Kontraktionsschwäche des Detrusors. <b>2007</b> , 36, 150-155	
456	Bibliography. Current world literature. Female urology. <b>2007</b> , 17, 287-90	
455	Botulinum toxin B is not an effective treatment of refractory overactive bladder. <b>2007</b> , 69, 69-73	18

454	Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection. <b>2007</b> , 69, 575.e13-5		8
453	[Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity]. <b>2007</b> , 50, 651-60		7
452	Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. <b>2007</b> , 88, 646-52		89
451	Applications of Botulinum toxin in urogynaecology. <b>2007</b> , 133, 4-11		19
450	[Multimuscle treatment of spasticity in adults patients with botulinum toxin]. <b>2007</b> , 50 Suppl 1, S4-6		2
449	Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going. <b>2007</b> , 4, 379-86		10
448	Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. <b>2007</b> , 41, 335-40		107
447	Operative Neuromodulation. <b>2007</b> ,		3
446	Therapeutic Uses of Botulinum Toxin. <b>2007</b> ,		2
445	Therapeutic Management of Incontinence and Pelvic Pain. <b>2007</b> ,		5
444	Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. <i>Journal of Urology</i> , <b>2007</b> , 177, 2231-6	2.5	237
443	Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. <i>Journal of Urology</i> , <b>2007</b> , 177, 1011-4	2.5	83
442	[Sensory innervation of the bladder: clinical and therapeutic implications]. <b>2007</b> , 17, 5-11		5
441	[Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections]. <b>2007</b> , 17, 568-75		5
440	Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. <i>Journal of Urology</i> , <b>2007</b> , 177, 1006-10; discussion 1010	2.5	38
439	[Treatment of vesicoureteric reflux and neurogenic bladder]. <b>2007</b> , 17, 470-2		6
438	Botulinum toxin injections for adults with overactive bladder syndrome. <b>2007</b> , CD005493		39
437	Botulinum toxin injection: a review of injection principles and protocols. <b>2007</b> , 33, 132-41		16

- 436 Botulinum toxin use in the lower urinary tract. **2007**, 7, 808-17
- 435 Electrical stimulation of sacral dermatomes in multiple sclerosis patients with neurogenic detrusor overactivity. **2007**, 26, 525-530 18
- 434 Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. **2007**, 26, 531-536 27
- 433 Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. **2007**, 26, 920-7 59
- 432 Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. **2007**, 62, 452-7 115
- 431 Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects. **2007**, 45, 535-41 17
- 430 Botulinum toxin A in the overactive bladder: current status and future directions. **2007**, 99, 247-62 61
- 429 Overactive bladder pharmacotherapy: what does the future hold?. **2007**, 99 Suppl 3, 13-6 8
- 428 Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. **2007**, 100, 1075-80 23
- 427 Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. **2007**, 100, 1302-6 62
- 426 Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity. **2007**, 51, 201-11 16
- 425 Acute urodynamic effects of posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with MS. **2007**, 51, 464-70; discussion 471-2 41
- 424 Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. **2007**, 52, 850-8 82
- 423 Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. **2007**, 52, 1729-35 72
- 422 Words of wisdom. Re: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. **2007**, 52, 1793-4 1
- 421 Botulinum toxin: from life-threatening disease to novel medical therapy. **2007**, 196, 7-15 35
- 420 Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea. **2007**, 12, 275-90 24
- 419 Current and future trends in the management of overactive bladder. **2007**, 18, 81-94 13

418	Can the ice-water test predict the outcome of intradetrusor injections of botulinum toxin in patients with neurogenic bladder dysfunction?. <b>2007</b> , 25, 613-7	3
417	[Botulinum toxin for the treatment of neurogenic detrusor hyperactivity. Consensus paper on use for neurogenic bladder dysfunction]. <b>2007</b> , 46, 293-6	6
416	[Botulinum toxin A injection for treatment-refractory giggle incontinence]. <b>2007</b> , 46, 773-5	9
415	Update on use of botulinum toxin to treat overactive bladder. <b>2007</b> , 2, 65-70	
414	Sacral neuromodulation for the treatment of overactive bladder in men. <b>2007</b> , 2, 117-123	
413	Update on bladder evaluation recommendations and bladder management guideline in patients with spinal cord injury. <b>2007</b> , 2, 134-140	2
412	Management of neurogenic voiding dysfunction in the male patient. <b>2007</b> , 2, 173-179	2
411	Repeated botulinum toxin injection for idiopathic overactive bladder: will chemodenervation become a long-term solution?. <b>2007</b> , 8, 419-24	6
410	Neuromodulation et toxine botulique dans les hyperactivit�s v�sicales neurog�nes de l'enfant. <b>2007</b> , 2, 244-248	
409	Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. <b>2008</b> , 19, 583-98	21
408	[Botulinum toxin for the treatment of overactive bladder--an overview]. <b>2008</b> , 47, 46-53	3
407	Intravesical strategies to manage the neurogenic bladder. <b>2008</b> , 3, 133-139	1
406	Augmentation cystoplasty: what are the indications?. <b>2008</b> , 9, 452-8	36
405	Le traitement par voie intrath�cale des troubles neurop�iniaux. <b>2008</b> , 3, 315-318	
404	The use of botulinum neurotoxin type A (BoNTA) in urology. <b>2008</b> , 115, 593-605	26
403	Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. <b>2008</b> , 27, 311-4	45
402	Intradetrusor botulinum toxin injections for overactive bladder. <b>2008</b> , 13, 27-28	
401	The neural control of micturition. <b>2008</b> , 9, 453-66	908

400	Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. <b>2008</b> , 15, 407-15; discussion 415	49
399	Re: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. <b>2008</b> , 101, 515-6; author reply 516-7	2
398	Reply. <b>2008</b> , 101, 516-517	
397	Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis. <b>2008</b> , 102, 704-6	38
396	Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application. <b>2008</b> , 102 Suppl 1, 2-6	13
395	Botulinum toxin: future developments. <b>2008</b> , 102 Suppl 1, 20-2	9
394	Health economics and intradetrusor injections of botulinum for the treatment of detrusor overactivity. <b>2008</b> , 102 Suppl 1, 17-9	8
393	Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. <b>2008</b> , 53, 613-8	100
392	Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. <b>2008</b> , 53, 1013-19	97
391	Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. <b>2008</b> , 53, 275-87	196
390	Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. <b>2008</b> , 54, 181-7	38
389	Botulinum toxin a era: little steps towards a better understanding. <b>2008</b> , 54, 25-7	2
388	Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. <b>2008</b> , 53, 1245-53	110
387	Neurotoxin Versus Neuromodulation for the Treatment of Refractory Overactive Bladder Syndrome. <b>2008</b> , 20, 109-111	1
386	Emerging drugs for treatment of overactive bladder and detrusor overactivity. <b>2008</b> , 13, 431-46	18
385	[Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients]. <b>2008</b> , 51, 315-21	7
384	[Peripheral electrical stimulation in neurogenic bladder]. <b>2008</b> , 51, 473-8	3
383	Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. <b>2008</b> , 71, 455-9	36

382	Acute effect of posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with multiple sclerosis: urodynamic study. <b>2008</b> , 71, 641-5		68
381	Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection. <b>2008</b> , 72, 1056-60		26
380	Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. <i>Journal of Urology</i> , <b>2008</b> , 180, 2522-6	2.5	52
379	[Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder]. <b>2008</b> , 18, 449-55		0
378	Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <b>2008</b> , 70, 1707-14		170
377	Pharmacotherapy of overactive bladder syndrome. <b>2008</b> , 1, 163-75		1
376	Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neurotoxin. <b>2008</b> , 5, 120-1		2
375	Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. <b>2008</b> , 5, 319-28		93
374	Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. <b>2008</b> , 31, 157-65		43
373	Patient Tolerability of Botulinum Toxin Type A Injections Under Local Anesthesia Using a Rigid Cystoscope. <b>2008</b> , 14, 179-184		2
372	Botulinum toxin: new option for refractory lower urinary tract symptoms in women. <b>2008</b> , 51, 176-86		3
371	Botulinum Toxin for Lower Urinary Tract Symptoms in Women. <b>2008</b> , 14, 135-161		
370	An effective day case treatment combination for refractory neuropathic mixed incontinence. <b>2008</b> , 34, 63-71; discussion 71-2		11
369	Botulinum toxin in the treatment of overactive bladder. <b>2008</b> , 75, 4-13		1
368	PHARMACOLOGIC NEUROMODULATION. <b>2008</b> , 257-265		
367	Investigational Drug Therapies for Overactive Bladder Syndrome: The Potential Alternatives to Anticholinergics. <b>2009</b> , 76, 161-177		1
366	Mechanism of Action of Botulinum Neurotoxin in the Lower Urinary Tract. <b>2009</b> , 231-239.e1		1
365	Botulinum Toxin in Overactive Bladder. <b>2009</b> , 240-256		1

364	Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. <b>2009</b> , 56, 700-6	138
363	Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. <b>2009</b> , 55, 705-11	109
362	Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. <b>2009</b> , 55, 711-2	
361	Botulinum neurotoxin type A: the poison that can treat the sick. <b>2009</b> , 55, 560-2	2
360	Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. <b>2009</b> , 55, 100-19	217
359	EAU guidelines on neurogenic lower urinary tract dysfunction. <b>2009</b> , 56, 81-8	338
358	The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. <b>2009</b> , 28, 964-8	76
357	39th Annual Meeting of the International Continence Society San Francisco, USA 29 September - 6 October, 2009. <b>2009</b> , 28, 567-935	2
356	Botulinum toxin in paediatric urology: a systematic literature review. <b>2009</b> , 25, 19-23	22
355	Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity. <b>2009</b> , 41, 805-13	19
354	Clinically isolated syndrome and multiple sclerosis: rethinking the arsenal. <b>2009</b> , 11, 193-202	6
353	Neuromodulation for urinary dysfunction. <b>2009</b> , 4, 139-144	
352	Neuromodulation versus medication for overactive bladder: the case for early intervention. <b>2009</b> , 10, 342-6	8
351	Recommandations de bonne pratique clinique pour le suivi des patients neurologiques après injection de toxine botulique intradétrusorienne. <b>2009</b> , 4, 53-59	1
350	Intérêt et résultats de l'utilisation de la toxine botulique dans l'hyperactivité détrusorienne d'origine neurologique. <b>2009</b> , 4, 60-66	
349	A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. <b>2009</b> , 27, 397-403	48
348	Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. <b>2009</b> , 9, 18	20
347	Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?. <b>2009</b> , 103, 630-4	39

346	Concomitant repeated intravesical injections of botulinum toxin-type A and laparoscopic antegrade continence enema; a new solution for an old problem. <b>2009</b> , 103, 1248-54		3
345	Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. <b>2009</b> , 103, 1509-15		53
344	Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study. <b>2009</b> , 104, 651-6		32
343	Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. <b>2009</b> , 104, 1246-50		58
342	A UK consensus on the management of the bladder in multiple sclerosis. <b>2009</b> , 80, 470-7		94
341	Development of future indications for BOTOX. <b>2009</b> , 54, 668-74		17
340	Botulinum toxin in the treatment of OAB, BPH, and IC. <b>2009</b> , 54, 639-46		19
339	Afferent nerve regulation of bladder function in health and disease. <b>2009</b> , 91-138		169
338	Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. <i>Journal of Urology</i> , <b>2009</b> , 181, 2608-15	2.5	146
337	Quelles peuvent être les futures applications de la toxine botulique en urologie en dehors des vessies hyperactives des patients neurologiques?. <b>2009</b> , 19, F91-F94		
336	[Criteria and best clinical practice guidelines for first intradetrusor injection of botulinum toxin type A to treat neurogenic detrusor overactivity]. <b>2009</b> , 19, 372-82		5
335	What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. <i>Journal of Urology</i> , <b>2009</b> , 181, 1773-8	2.5	55
334	Botox therapy for ischemic digits. <b>2009</b> , 124, 191-201		116
333	Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?. <b>2009</b> , 19, 347-52		13
332	Rehabilitation of pediatric spinal cord injury: From acute medical care to rehabilitation and beyond. <b>2009</b> , 2, 13-27		5
331	Botulinum toxin in urological disorders. 153-160		
330	Botulinum toxin: historical perspective and treatment of neurogenic and idiopathic overactive bladder. <b>2009</b> , 6, 165-175		1
329	Urinary Tract Dysfunction in Neurological Disorders. <b>2010</b> , 42, E8-E23		2

328	Approach and evaluation of neurogenic bladder dysfunction. 61-78	4
327	Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. <b>2010</b> , 106, 1677-80	29
326	Neuropathic bladder dysfunction. <b>2010</b> , 15, 23-28	6
325	Abstracts from the Joint Meeting of the International Continence Society and the International Urogynecological Association. Toronto, Canada. August 23-27, 2010. <b>2010</b> , 21 Suppl 1, S1-428	13
324	Alternative approaches to sacral nerve stimulation. <b>2010</b> , 21, 1559-63	25
323	Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. <b>2010</b> , 28, 385-90	43
322	Current Status of Botulinum Toxin for Neurogenic Bladder Dysfunction. <b>2010</b> , 5, 87-97	
321	Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. <b>2010</b> , 19, 323-31	14
320	In the human urothelium and suburothelium, intradetrusor botulinum neurotoxin type A does not induce apoptosis: preliminary results. <b>2010</b> , 57, 879-83	8
319	Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses. <b>2010</b> , 58, 759-66	38
318	ICS-IUGA 2010 Scientific Programme, Wednesday 25th August 2010. <b>2010</b> , 29, 805-1255	10
317	Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. <b>2010</b> , 25, 2211-8	117
316	Botulinum toxin for the lower urinary tract. <b>2010</b> , 105, 1046-58	21
315	Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity. <b>2010</b> , 36, 732-7	4
314	Cortical and subcortical disorders. 167-186	
313	Multiple sclerosis and other non-compressive myelopathies. 220-240	1
312	Neurogenic bladder dysfunction: pharmacological interventional approaches. 89-111	2
311	Bladder dysfunction in multiple sclerosis. 190-200	

310	Spasticity in multiple sclerosis. 165-175		
309	Social, economic, and health utility considerations in the treatment of overactive bladder. <b>2010</b> , 2, 11-24		20
308	The unusual history and the urological applications of botulinum neurotoxin. <b>2010</b> , 85, 125-30		10
307	Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. <i>Journal of Urology</i> , <b>2010</b> , 183, 598-602	2.5	43
306	Botox <sup>®</sup> in urology--will it become standard of care for urge urinary incontinence?. <i>Journal of Urology</i> , <b>2010</b> , 184, 2235-6	2.5	2
305	Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial. <i>Journal of Urology</i> , <b>2010</b> , 184, 2423-8	2.5	67
304	Non-neurogenic elimination disorders in children. <b>2010</b> , 6, 338-45		23
303	Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. <b>2010</b> , 76, 835-40		39
302	Rehabilitation in practice: neurogenic lower urinary tract dysfunction and its management. <b>2010</b> , 24, 579-89		43
301	[Guidelines for treatment of urinary incontinence in women due to refractory idiopathic vesical hyperactivity with botulinum toxin A]. <b>2010</b> , 20 Suppl 2, S170-3		3
300	Noodzaak tot zelfkatheterisatie na intravesicale botulinetoxine-A-injecties. <b>2011</b> , 1, 137-140		
299	Botulinum toxin injections for adults with overactive bladder syndrome. <b>2011</b> , CD005493		91
298	Pharmacotherapy for overactive bladder: minimally invasive treatment -- botulinum toxins. <b>2011</b> , 12, 1029-39		3
297	Botulinum Toxin in Urology. <b>2011</b> ,		4
296	A simplified technique for botulinum toxin injections in children with neurogenic bladder. <i>Journal of Urology</i> , <b>2011</b> , 185, 2558-62	2.5	6
295	Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. <i>Journal of Urology</i> , <b>2011</b> , 185, 2229-35	2.5	109
294	Botulinum A Toxin Intravesical Injections in the Treatment of Refractory Overactive Bladder in Patients with Parkinson's Disease. <b>2011</b> ,		
293	Repeat intradetrusor injections of onabotulinum toxin a for refractory idiopathic overactive bladder patients: a single-center experience. <b>2011</b> , 17, 253-7		13

292	Management of bladder and sexual dysfunction in multiple sclerosis. 676-695	
291	Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. <b>2011</b> , 37, 642-8	25
290	Multiple sclerosis and bladder dysfunction. <b>2011</b> , 7, 645-654	1
289	Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. <b>2011</b> , 107, 1786-92	20
288	Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). <b>2011</b> , 60, 784-95	151
287	Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. <b>2011</b> , 60, 742-50	332
286	OnabotulinumtoxinA in refractory neurogenic detrusor overactivity. <b>2011</b> , 60, 751-2	4
285	Botulinetoxine-injecties bij klachten van een overactieve blaas. <b>2011</b> , 1, 51-53	
284	Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. <b>2011</b> , 29, 51-7	26
283	Treatment of Neurogenic Voiding Dysfunction: An Update. <b>2011</b> , 6, 37-44	1
282	Current Use of Botulinum A Toxin in Overactive Bladder Management. <b>2011</b> , 6, 7-12	
281	Current Concepts in Female Neurogenic Voiding Dysfunction. <b>2011</b> , 6, 150-158	1
280	Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management. <b>2011</b> , 12, 404-12	27
279	Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. <b>2011</b> , 30, 1242-8	61
278	Central inhibitory effect of intravesically applied botulinum toxin A in chronic spinal cord injury. <b>2011</b> , 30, 1376-81	19
277	Repeated Botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele. <b>2011</b> , 30, 1546-9	29
276	Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries. <b>2011</b> , 30, 1541-5	23
275	Systematic review of overactive bladder therapy in females. <b>2011</b> , 5, S139-42	10

274 Les incontinences urinaires de l'homme. **2011**,

273 [Overactive bladder syndrome: the social and economic perspective]. **2011**, 78, 241-56

6

272 Botulinum toxin A: First-line therapy for idiopathic detrusor overactivity. **2011**, 5, 207-9

2

271 Nörolojik Hastalıklara İncil Gelişen Aktif Mesaneyeye Yıllık Botulinum Toksini Uygulamaları  
**2011**, 48, 1-1

270 Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients: a literature overview. **2012**, 50, 8-13

21

269 Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. **2012**, 12, 763-75

11

268 [Repeated injection of botulinum toxin a in patients with neurogenic bladder: our experience].  
**2012**, 79 Suppl 19, 9-14

267 Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity. **2012**, 4, 29-34

3

266 Toxina botulífica en el tratamiento de la hiperactividad vesical neurogēna. **2012**, 44, 1-7

265 [Unconventional treatment procedures of the bladder in paraplegia and myelomeningocele]. **2012**, 51, 1692-6

1

264 Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults. **2012**, 30, 451-6

1

263 Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). **2012**, 62, 507-14

110

262 Evolution of the management of acquired neurogenic bladder in children using intradetrusor botulinum toxin type A injections: 5-year experience and perspectives. **2012**, 8, 497-503

10

261 Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. *Journal of Urology*, **2012**, 187, 2131-9

2.5 250

260 [Management of neurogenic bladder patients in France: a survey carried out by the French-speaking neurourology study group (GENULF)]. **2012**, 22, 540-8

4

259 Intravesical Botulinum Toxin for Overactive Bladder Syndrome without Detrusor Overactivity. **2012**, 5, 169-173

3

258 [Botulinum toxin A intradetrusor injections in consultation: single center experience during 2 years]. **2012**, 22, 214-9

257 Bladder Injections for Refractory Overactive Bladder. **2012**, 1625-1632

256	Botulinum toxin therapy for the management of lower urinary tract symptoms [has this come of age?. <b>2012</b> , 9, e35-e39	
255	[Highlighting differences in the management of neurogenic bladder existing between urologists and physiatrists: A survey conducted among 383 specialists]. <b>2012</b> , 41, e599-608	5
254	Urinary Incontinence. <b>2012</b> , 635-692	2
253	Botox(®) for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection. <b>2012</b> , 286, 923-9	16
252	The role of neuromodulation in patients with neurogenic overactive bladder. <b>2012</b> , 13, 343-7	24
251	Overactive Bladder in Clinical Practice. <b>2012</b> ,	4
250	OnabotulinumtoxinA in the treatment of neurogenic bladder. <b>2012</b> , 6, 299-306	2
249	Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. <b>2012</b> , 2012, 463574	10
248	Overactive bladder in men: treatment options. <b>2012</b> , 3, 13-16	
247	Lower Urinary Tract Dysfunction in Multiple Sclerosis. <b>2012</b> , 7, 97-104	2
246	Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment. <b>2012</b> , 30, 367-73	9
245	Botulinum toxin type A for the treatment of lower urinary tract disorders. <b>2012</b> , 19, 202-15	32
244	Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity. <b>2012</b> , 61, 1054-61	23
243	[Botulinum toxin for neurogenic bladder dysfunction]. <b>2012</b> , 51, 198-203	8
242	Botulinum toxin injection for lower urinary tract dysfunction. <b>2013</b> , 20, 40-55	22
241	Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). <b>2013</b> , 111, 106-13	81
240	Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system. <b>2013</b> , 260, 701-13	23
239	Neurogenic lower urinary tract dysfunction. <b>2013</b> , 110, 209-20	18

238	An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. <b>2013</b> , 31, 1469-74	30
237	Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review. <b>2013</b> , 73, 1055-66	32
236	Tension-Free Vaginal Tape Plus Intradetrusor BOTOX® Injection Versus Tension-Free Vaginal Tape Versus Intradetrusor BOTOX Injection in Equal-Weight Mixed Urinary Incontinence: A Prospective Randomized Study. <b>2013</b> , 29, 235-240	0
235	OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology. <b>2013</b> , 30, 819-33	57
234	Botulinum toxin treatment for bladder dysfunction. <b>2013</b> , 20, 956-62	17
233	Principios de acción e indicaciones de la toxina botulínica en el tratamiento de la hiperactividad vesical del adulto. <b>2013</b> , 45, 1-12	
232	The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients. <b>2013</b> , 59, 261-8	19
231	Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury. <b>2013</b> , 94, 1473-81	27
230	Botulinum toxin type A injection for neurogenic detrusor overactivity: clinical outcome in Japanese patients. <b>2013</b> , 20, 94-9	5
229	Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. <b>2013</b> , 67, 129-40	24
228	Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. <b>2013</b> , 36, 402-19	43
227	OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. <b>2013</b> , 81, 841-8	37
226	Intradetrusor injection of botulinum toxin for the management of refractory overactive bladder syndrome: an update. <b>2013</b> , 20, 351-5	0
225	Therapeutic outcome and quality of life between urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia. <b>2013</b> , 67, 1044-9	19
224	Efficacy of botulinum toxin a intradetrusor injections for non-neurogenic urinary urge incontinence: a randomized double-blind controlled trial. <b>2013</b> , 35, 53-60	9
223	The Successful and Novel Treatment of Non-Neurogenic Detrusor-External Sphincter Dyssynergia (DESD) with Botulinum Toxin A. <b>2013</b> , 22, 93-98	1
222	Botulinum toxin A should not be first-line therapy for overactivebladder. <b>2013</b> , 5, 204	
221	Systematic review of overactive bladder therapy in females. <b>2013</b> , 5, 139	

220	Botulinum toxin A: First-line therapy for idiopathic detrusor overactivity. <b>2013</b> , 5, 204	
219	Emerging treatments for overactive bladder: clinical potential of botulinum toxins. <b>2014</b> , 6, 51-7	9
218	Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA. <b>2014</b> , 4, 65-75	3
217	Therapeutic Uses of Botulinum Toxin. <b>2014</b> , 05,	3
216	Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice. <b>2014</b> , 6, 34-42	14
215	Decade in review-urinary incontinence: advances in female urology and voiding dysfunction. <b>2014</b> , 11, 613-4	
214	Onabotulinum Toxin A: A Therapeutic Option for Refractory Neurogenic Detrusor Overactivity and Idiopathic Overactive Bladder. <b>2014</b> , 34, 165	3
213	Neurogenic bladder in patients with traumatic spinal cord injury: treatment and follow-up. <b>2014</b> , 52, 462-7	17
212	Botulinum Toxin A Intradetrusor Injection for Treating Neurogenic Detrusor Overactivity, A Single Centre Experience. <b>2014</b> , 6, 162-6	
211	The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients. <b>2014</b> , 33, 129-34	20
210	Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. <b>2014</b> , 68, 731-42	25
209	Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). <b>2014</b> , 33 Suppl 3, S26-31	32
208	Minimally Invasive Therapy for Urinary Incontinence and Pelvic Organ Prolapse. <b>2014</b> ,	
207	Urinary incontinence in the young woman: treatment plans and options available. <b>2014</b> , 10, 201-17	7
206	Deep brain stimulation and multiple sclerosis: Therapeutic applications. <b>2014</b> , 3, 431-9	17
205	Urologic agents for treatment of bladder dysfunction in neurologic disease. <b>2014</b> , 16, 280	5
204	Voiding Dysfunction After Non-genitourinary Radical Pelvic Surgery. <b>2014</b> , 9, 234-241	
203	[Bacterial ecology and resistance to antibiotics in patients with neurogenic overactive bladder treated with intravesical botulinum toxin injections]. <b>2014</b> , 24, 744-9	1

202	OnabotulinumtoxinA (Botox(® )): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury. <b>2014</b> , 74, 1659-72		15
201	A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics. <b>2014</b> , 14, 66		8
200	Botulinum toxin for symptomatic therapy in multiple sclerosis. <b>2014</b> , 14, 463		17
199	Neural control of lower urinary tract and targets for pharmacological therapy. <b>2014</b> , 25, 1453-62		8
198	Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis: an open label, multicenter, prospective study. <i>Journal of Urology</i> , <b>2014</b> , 191, 697-702	2.5	29
197	OnabotulinumtoxinA and multiple sclerosis. <b>2014</b> , 57, 302-314		18
196	Botulinum toxin for the overactive bladder. <b>2015</b> , 164-188		
195	New treatments for neurogenic detrusor overactivity. <b>2015</b> , 5, 519-528		
194	. <b>2015</b> ,		
193	Hematuria following Botox treatment for upper limb spasticity: a case report. <b>2015</b> , 8, 619-22		4
192	OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review. <b>2015</b> , 41, 207-19		4
191	Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study. <b>2015</b> , 7, 3424-35		3
190	Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport® ) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?. <b>2015</b> , 7, 5462-71		1
189	Evaluation and Management of Neurogenic Bladder: What Is New in China?. <b>2015</b> , 16, 18580-600		17
188	Neurogenic bladder in spinal cord injury patients. <b>2015</b> , 7, 85-99		100
187	Dysfunction of lower urinary tract in patients with spinal cord injury. <b>2015</b> , 130, 247-67		10
186	Lower urinary tract dysfunction in patients with multiple sclerosis. <b>2015</b> , 130, 371-81		22
185	Management and rehabilitation of neurologic patients with lower urinary tract dysfunction. <b>2015</b> , 130, 451-68		11

184	Stemming the Tide: Infectious Complications After Prostate Biopsy. <b>2015</b> , 33, 893, 896-7	1
183	Results of intravesical botulinum toxin A in men with idiopathic overactive bladder symptoms. <b>2015</b> , 8, 104-109	1
182	[Definition of botulinum toxin failure in neurogenic detrusor overactivity: Preliminary results of the DETOX survey]. <b>2015</b> , 25, 1219-24	8
181	Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan. <b>2015</b> , 22, 306-9	7
180	Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity. <b>2015</b> , 39, 217-21	2
179	Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity. <b>2015</b> , 39, 217-221	
178	Sexuality for women with spinal cord injury. <b>2015</b> , 41, 238-53	15
177	Effect of intravesical botulinum neurotoxin-A injection on detrusor hyperreflexia in spinal cord injured patients. <b>2015</b> , 65, 327-31	1
176	OnabotulinumtoxinA (Botox A) for Neurogenic Detrusor; Evidence for 200 U vs. 300 U. <b>2015</b> , 10, 315-317	
175	Editorial comment to Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan. <b>2015</b> , 22, 310	
174	Current and potential urological applications of botulinum toxin A. <b>2015</b> , 12, 519-33	21
173	[Seniority of neurobladder and effectiveness of a first intradetrusor injection of botulinum toxin]. <b>2015</b> , 25, 642-8	1
172	Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity. <b>2015</b> , 114, 583-9	13
171	New pharmacotherapy for treating overactive bladder: mirabegron and botulinum toxin. <b>2016</b> , 59, 795	
170	Secondary and tertiary treatments for multiple sclerosis patients with urinary symptoms. <b>2016</b> , 57, 377-383	9
169	Intra Detrusor Botulinum Toxin and Lower Limbs Motor Deficit: About 2 Clinical Cases. <b>2016</b> , 06,	
168	Intravesical Botulinum Toxin for Persistent Autonomic Dysreflexia in a Pediatric Patient. <b>2016</b> , 2016, 4569684	4
167	Botulinum toxin A for the Treatment of Overactive Bladder. <b>2016</b> , 8,	26

166	Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature. <b>2016</b> , 8, 88	18
165	Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2016</b> , 11, e0159307	24
164	Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia. <b>2016</b> , 48, 683-687	14
163	Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity. <b>2016</b> , 35, 267-70	17
162	Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity. <b>2016</b> , 6, 33197	14
161	Management of neurogenic bladder in patients with multiple sclerosis. <b>2016</b> , 13, 275-88	68
160	Botulinum toxin therapy for neurogenic detrusor hyperactivity versus augmentation enterocystoplasty: impact on the quality of life of patients with SCI. <b>2016</b> , 54, 1031-1035	11
159	Modeling of chronic radiation-induced cystitis in mice. <b>2016</b> , 1, 333-343	18
158	Pediatric Bladder Reconstruction. <b>2016</b> , 11, 211-217	
157	Prospective evaluation of antibiotic treatment for urological procedure in patients presenting with neurogenic bladder. <b>2016</b> , 46, 300-7	7
156	Therapeutic Potential of Human Chorionic Gonadotropin Against Overactive Bladder. <b>2016</b> , 23, 1122-8	2
155	Functional Urologic Surgery in Neurogenic and Oncologic Diseases. <b>2016</b> ,	
154	Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA. <b>2016</b> , 17, 27	16
153	Use of Botulinum Toxin in Urologic Diseases. <b>2016</b> , 91, 21-32	11
152	Modeling and Treatment of Radiation Cystitis. <b>2016</b> , 88, 14-21	29
151	Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury. <b>2016</b> , 33, 1651-7	24
150	Therapeutic Potential of Human Chorionic Gonadotropin Against Painful Bladder Syndrome/Interstitial Cystitis. <b>2016</b> , 23, 1451-1458	0
149	Botulinum Toxin to Treat Neurogenic Bladder. <b>2016</b> , 36, 5-9	9

148	British Association of Paediatric Urologists consensus statement on the management of the neuropathic bladder. <b>2016</b> , 12, 76-87	26
147	Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750U for treating neurological detrusor overactivity. <b>2016</b> , 34, 755-61	11
146	Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study. <b>2017</b> , 36, 734-739	12
145	Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study. <b>2017</b> , 36, 457-462	21
144	Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results. <b>2017</b> , 36, 104-110	36
143	Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. <b>2017</b> , 36, 338-343	3
142	Bedside Approach to Autonomic Disorders. <b>2017</b> ,	1
141	Botulinum Toxin Treatment in Multiple Sclerosis-a Review. <b>2017</b> , 19, 33	8
140	Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era. <b>2017</b> , 18, 64	6
139	Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity. <b>2017</b> , 44, 463-474	13
138	Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?. <b>2017</b> , 120, 848-854	8
137	Overactive bladder treatment: application of methylene blue to improve the injection technique of onabotulinum toxin A. <b>2017</b> , 51, 474-478	6
136	Clinical Factors to Decide Between Sacral Neuromodulation and Onabotulinum Toxin When Is One Clearly Better?. <b>2017</b> , 12, 328-336	
135	Botulinum Toxin Therapy for Nonmotor Aspects of Parkinson's Disease. <b>2017</b> , 134, 1111-1142	4
134	Intravesical Botulinum Toxin for Neurogenic Bladder Can We Just Irrigate the Bladder with Botulinumtoxin?. <b>2017</b> , 12, 343-348	
133	Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis. <b>2017</b> , 21, 53-61	5
132	Use of botulinum toxin for voiding dysfunction. <b>2017</b> , 6, 234-251	6
131	Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder. <b>2018</b> , 22, 79-84	3

130	Autonomic dysreflexia after spinal cord injury: Systemic pathophysiology and methods of management. <b>2018</b> , 209, 59-70	99
129	Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. <b>2018</b> , 37, 799-806	15
128	Incontinence Due to Neurogenic Detrusor Overactivity. <b>2018</b> , 77-113	
127	Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Executive summary. <b>2019</b> , 13, 156-165	5
126	Bladder Injections for Refractory Overactive Bladder. <b>2018</b> , 1775-1783	
125	Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text. <b>2019</b> , 13, E157-E176	12
124	5. Neurogene Blasen- und Darmentleerungsstörung. <b>2018</b> , 159-238	
123	Management of Neurogenic Lower Urinary Tract Dysfunction. 202-217	
122	Neuro-Urology. <b>2018</b> ,	1
121	Minimally Invasive Treatments. <b>2018</b> , 387-404	
120	Bladder diverticuli following injection of onabotulinum toxin A in a patient with multiple sclerosis and autosomal dominant polycystic kidney disease. <b>2018</b> , 13, 1021-1024	1
119	Non-surgical urologic management of neurogenic bladder after spinal cord injury. <b>2018</b> , 36, 1555-1568	28
118	Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial. <b>2018</b> , 16, eAO4207	7
117	Incontinence. <b>2018</b> , 193-206	
116	Safely Avoiding Surgery in Adult Neurogenic Bladder. <b>2018</b> , 13, 169-177	2
115	AbobotulinumtoxinA for the treatment of overactive bladder. <b>2018</b> , 18, 1005-1013	1
114	What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens. <b>2019</b> , 30, 701-704	7
113	Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis. <b>2019</b> , 41, 937-945	1

112	The Current Role of Botox in a Pediatric Neurogenic Bladder Condition. <b>2019</b> , 14, 115-123	1
111	Botulinum Toxin Type A Injection After Failure of Augmentation Enterocystoplasty Performed for Neurogenic Detrusor Overactivity: Preliminary Results of a Salvage Strategy. The ENTEROTOX Study. <b>2019</b> , 129, 43-47	6
110	Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons. <b>2019</b> , 11,	8
109	[Non continent urinary diversion and other bladder managements in patients with multiple sclerosis]. <b>2019</b> , 29, 572-578	0
108	Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury. <b>2019</b> , 118, 125-133	1
107	Neuromodulation for functional bladder disorders in patients with multiple sclerosis. <b>2020</b> , 26, 1274-1280	2
106	Urodynamics in patients with multiple sclerosis: A consensus statement from a urodynamic experts working group. <b>2020</b> , 39, 73-82	4
105	Botulinum Toxin Treatment in Surgery, Dentistry, and Veterinary Medicine. <b>2020</b> ,	
104	Can clinical and urodynamic parameters predict the occurrence of neutralizing antibodies in therapy failure of intradetrusor onabotulinumtoxin A injections in patients with spinal cord injury?. <b>2020</b> , 20, 113	2
103	Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites. <b>2020</b> , 10, 12851	9
102	Intradetrusor botulinum toxin injections (300 units) for the treatment of poorly compliant bladders in patients with adult neurogenic lower urinary tract dysfunction. <b>2020</b> , 39, 2322-2328	1
101	Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients. <b>2020</b> , 21, 1449-1454	5
100	Female Pelvic Surgery. <b>2020</b> ,	
99	A single-blind randomized control trial of trigonal versus nontrigonal Botulinum toxin-A injections for patients with urinary incontinence and poor bladder compliance secondary to spinal cord injury. <b>2021</b> , 44, 757-764	3
98	Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder. <b>2019</b> , 10, 1618	11
97	Are 200 units of onabotulinumtoxin A sufficient for the suppression of neurogenic detrusor overactivity in individuals with established 300-unit botulinum toxin treatment? A retrospective cohort study. <b>2021</b> , 39, 543-547	1
96	Trigonal-sparing versus trigonal-involved Botox injection for treatment of idiopathic overactive bladder: A randomized clinical trial. <b>2021</b> , 13, 22-30	4
95	Short-term reproducibility of cystometry in multiple sclerosis patients. <b>2021</b> , 31, 169-174	0

94	Beyond botulinum neurotoxin A for chemodenervation of the bladder. <b>2021</b> , 31, 140-146	1
93	Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?. <b>2021</b> , 33, 101-107	1
92	Immunogenicity to Botulinum Toxin Type A: A Systematic Review With Meta-Analysis Across Therapeutic Indications. <b>2021</b> ,	4
91	In Patients with Neurogenic Detrusor Overactivity and Hinman's Syndrome: Would Intravesical Botox Injections Decrease the Incidence of Symptomatic Urinary Tract Infections. <b>2021</b> , 13, 659-663	0
90	Clinical Use of Botulinum Neurotoxin: Urogenital Disorders Including Overactive Bladder. <b>2014</b> , 123-152	1
89	Botulinum Toxin Bladder Injection in the Treatment of Neurogenic Detrusor Overactivity and Idiopathic OAB. <b>2016</b> , 171-186	1
88	Botulinum Toxin for Neurogenic Detrusor Overactivity. <b>2011</b> , 29-59	1
87	Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A. <b>2011</b> , 345-74	9
86	Conservative Management of Urinary Incontinence. <b>2012</b> , 2003-2025.e4	5
85	Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity. <b>2016</b> , 12, 624-631	4
84	Medical Management of Neurogenic Bladder for Children and Adults: A Review. <b>2019</b> , 25, 195-204	7
83	Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity. <b>2010</b> , 36, 66-74	13
82	A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages. <b>2017</b> , 8, 90338-90350	9
81	Part IX Complications. <b>2008</b> , 851-852	1
80	Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review). <b>2020</b> , 20, 117-120	7
79	Pharmacological management of hemodynamic complications following spinal cord injury. <b>2009</b> , 32, 331	19
78	Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies. <b>2016</b> , 5, 127-35	36
77	The role of botulinum toxin A in treating neurogenic bladder. <b>2016</b> , 5, 63-71	15

76	Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. <b>2015</b> , 128, 963-8	18
75	The use of botulinum toxin for the treatment of overactive bladder syndrome. <b>2013</b> , 29, 2-11	19
74	The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA. <b>2015</b> , 7, 320-4	1
73	Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. <b>2020</b> , 61, S33-S42	16
72	What is the feasibility of switching to 200IU OnabotulinumtoxinA in patients with detrusor overactivity who have previously received 300IU?. <b>2014</b> , 67, 35-40	6
71	Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-analysis. <b>2018</b> , 22, 275-286	15
70	The Effects of Intradetrusor BoNT-A Injections on Vesicoureteral Reflux in Children With Myelodysplasia. <b>2019</b> , 23, 321-326	2
69	Botulinum toxin in neurogenic detrusor overactivity. <b>2012</b> , 16, 139-43	4
68	How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?. <b>2016</b> , 5, 195-203	4
67	Radiofrequency sacral rhizotomy for the management of intolerable neurogenic bladder in spinal cord injured patients. <b>2012</b> , 36, 213-9	8
66	Onabotulinum toxin a (botox®) in the treatment of neurogenic bladder overactivity. <b>2012</b> , 4, 437-42	7
65	La rđducation et la rđadaptation des blessš mđullaires. <b>2005</b> , 189, 1159-1174	0
64	Management of lower urinary tract symptoms in men with progressive neurological disease. <b>2006</b> , 16, 30-36	3
63	References. <b>2006</b> , 811-946	
62	Managing symptoms in multiple sclerosis. <b>2006</b> , 87-108	
61	Urological Applications of Botulinum Toxin. <b>2007</b> , 213-220	
60	Uroneurology. <b>2008</b> , 751-762	
59	Urinary Incontinence: Clinical and Surgical Considerations. <b>2008</b> , 187-209	

- 58 Botulinum Toxin: An Effective Treatment for Urge Incontinence. **2009**, 257-274
- 57 Primary Urge Incontinence. **2009**, 393-409
- 56 Overactive Bladder and Incontinence. **2010**, 89-103
- 55 Biology and Mechanism of Action. **2011**, 13-26
- 54 Les traitements combinés : pharmacothérapie et sondage intermittent. **2011**, 303-310
- 53 The overactive bladder syndrome. **2011**, 813-835
- 52 Neurourology. **2011**, 256-271
- 51 Pharmacological Treatment of Overactive Bladder. **2012**, 83-113
- 50 Technologies for the Rehabilitation of Neurogenic Lower Urinary Tract Dysfunction. **2012**, 413-439
- 49 Les traitements de seconde intention de l'hyperactivité vésicale idiopathique. **2012**, 31, 104-108
- 48 Clinical Use of Botulinum Neurotoxin: Autonomic Conditions. **2014**, 95-121
- 47 Intravesical Therapy for Refractory Overactive Bladder and Detrusor Overactivity in Adults: Botulinum Toxin-A. **2014**, 135-154
- 46 Use of botulinum toxin in the treatment of urinary incontinence. **2016**, 17, 172-176 1
- 45 Therapeutic Outcome of Botulinum Toxin Type A for Patients with Low Bladder Compliance Secondary to Spinal Cord Injury. **2017**, 07, 207-211 1
- 44 Bladder and Sexual Dysfunction. **2017**, 81-100
- 43 Botulinum Toxin Treatment in Multiple Sclerosis. **2018**, 109-129
- 42 Applications of Botulinum Toxin in the Urinary Tract. **2018**, 49-65
- 41 The Description of Urodynamic Study for Bladder Dysfunction in Compressive Myelo- or Radiculo-pathy: A Prospective Study in an Institutional Setup. **2019**, 14, 828-833

40	Botulinum Toxin Therapy for Voiding Dysfunction. <b>2020</b> , 255-282	
39	Intravesical Botulinum Toxin for the Treatment of Overactive Bladder. <b>2021</b> , 365-373	
38	Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction. <b>2020</b> , 24, 301-312	6
37	Botulinum Toxin Treatment in Urological Disorders. <b>2020</b> , 297-308	
36	Evidence-Based Review of Current Botulinum Toxin Treatment Indications in Medicine. <b>2020</b> , 43-112	
35	Botulinum Toxin Injections to Treat Neurogenic Bladder Sphincter Dysfunction in Pediatric Patients. <b>2006</b> , 199-202	
34	Urological Applications. <b>2007</b> , 167-193	
33	Surgery for Urinary Incontinence. <b>2008</b> , 171-179	
32	Drugs Acting on the Lower Urinary Tract. <b>2008</b> , 181-184	
31	Sacral neuromodulation as a functional treatment of bladder overactivity. <b>2007</b> , 97, 315-22	1
30	Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. <b>2006</b> , 8, 198-208	25
29	Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. <b>2006</b> , 29, 527-73	152
28	Overactive bladder: pharmacologic treatments in the neurogenic population. <b>2008</b> , 10, 182-91	19
27	Treatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn't it effective in all patients?. <b>2015</b> , 4, 543-54	2
26	Botulinum Toxin Use in Neurourology. <b>2018</b> , 20, 84-93	3
25	[Interstitial cystitis: interventions and surgery - more than a last resort?]. <b>2021</b> , 52, 561-568	
24	50 years in urinary incontinence: a bibliometric analysis of the top 100 cited articles of the last 50 years.. <b>2022</b> , 1	0
23	BoNT/A in the Urinary Bladder-More to the Story than Silencing of Cholinergic Nerves.. <b>2022</b> , 14,	1

- 22 Quality of Life in Neurogenic Bladder Patients and Improvement after Botulinum Toxin Injection.
- 21 Interventional management and surgery of neurogenic lower urinary tract dysfunction in patients with chronic spinal cord injury: A urologist's perspective.. **2022**, 0
- 20 Intracavernosal OnabotulinumtoxinA Exerts a Synergistic Pro-Erectile Effect When Combined With Sildenafil in Spontaneously Hypertensive Rats.. **2022**, 0
- 19 Concomitant Detrusor and External Urethral Sphincter Botulinum Toxin-A Injections in Male Spinal Cord Injury Patients with Detrusor Overactivity and Detrusor Sphincter Dyssynergia.. **2022**, 1
- 18 Disease-modifying therapy for multiple sclerosis in clinical practice. 583-603
- 17 Botulinum Toxin: An Effective Treatment for Urge Incontinence. **2009**, 257-274
- 16 Primary Urge Incontinence. **2009**, 393-409
- 15 DataSheet\_1.docx. **2020**,
- 14 Patient perceived improvement and medication resumption rates after intradetrusor onabotulinumtoxinA for idiopathic urgency urinary incontinence.
- 13 Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?. **2022**, 14, 498 2
- 12 Urinary Tract Infection in Overactive Bladder: An Update on Pathophysiological Mechanisms. 13, 0
- 11 Impact of the suspension of neurogenic detrusor overactivity treatment with botulinum toxin due to the COVID-19 pandemic. 039156032211139
- 10 Management of neuropathic bladder secondary to spina bifida: Twenty years' experience with a conservative approach. 10,
- 9 Intravesical injection of botulinum toxin type a may be an effective treatment option for autonomic dysreflexia in patients with high-level spinal cord injury. 1-5 0
- 8 The translational implications of the science behind the overactive bladder and the role of OnabotulinumtoxinA. **2022**, 0
- 7 Posterior tibial nerve stimulation as a neuromodulation therapy in treatment of neurogenic overactive bladder in multiple sclerosis: A prospective randomized controlled study. **2022**, 68, 104252 0
- 6 Sustained Clinical Efficacy after Repeat Intradetrusor Botulinum Toxin Type A in the Treatment of Neurogenic Detrusor Overactivity. **2010**, 39, 152-153 0
- 5 Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison. 1-12 1

- 4 MESANE PATOLOJİLERİNDE BOTULİNİUM TOKSİNİ UYGULAMALARI: İKİ HASTA SERBİ SONUÇLARIMIZ. ○
- 3 Efficacy of overactive neurogenic bladder treatment: A systematic review of randomized controlled trials. **2022**, 94, 492-506 ○
- 2 Botulinum Toxin Type A for Refractory Neurogenic Detrusor Overactivity in Spinal Cord Injured Patients in Singapore. **2007**, 36, 11-17 2
- 1 Treating Neurogenic Lower Urinary Tract Dysfunction in Chronic Spinal Cord Injury Patients When Intravesical Botox Injection or Urethral Botox Injection Are Indicated. **2023**, 15, 288 ○